CTKB

+ Watchlist + Portfolio

Cytek Biosciences, Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $5.81
52-Week Range: $3.31 – $6.18
Market Cap: $763.00M
P/E (TTM): —
EPS (TTM): -0.62
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 2.37
PEG Ratio: —
Return on Equity: -23.04%
Return on Assets: -6.31%
Gross Margin: 51.88%
Operating Margin: -29.50%
Profit Margin: -38.98%
Current Ratio: 4.48
Debt/Equity: 0.08
Total Debt: $26.46M
Free Cash Flow: $9.30M
Revenue Growth: 5.60%
Earnings Growth: —
Enterprise Value: $527.46M

CTKB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$164.04M	$193.01M	$200.45M	$201.49M
Cost of Revenue	$63.06M	$83.59M	$89.35M	$97.03M
Gross Profit	$100.97M	$109.43M	$111.11M	$104.46M
Research & Development	$34.86M	$44.15M	$39.40M	$36.47M
Selling, General & Admin	$67.92M	$93.12M	$92.23M	$108.38M
Operating Expenses	$102.78M	$137.27M	$131.63M	$144.84M
Operating Income	-$1.80M	-$27.84M	-$20.52M	-$40.38M
EBITDA	$9.49M	-$4.41M	-$10.03M	-$17.39M
Pretax Income	$1.26M	-$15.71M	-$5.70M	-$29.84M
Income Tax	-$1.22M	-$3.56M	$320.00K	$36.70M
Net Income	$2.58M	-$12.15M	-$6.02M	-$66.54M
Diluted EPS	0.02	-0.09	-0.05	-0.52
Diluted Shares	138.56M	130.71M	130.61M	127.75M

CTKB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$296.60M	$167.30M	$98.72M	$90.85M
Receivables	$50.88M	$56.12M	$60.59M	$72.13M
Inventory	$48.15M	$60.88M	$43.89M	$48.43M
Current Assets	$454.02M	$392.06M	$396.45M	$392.00M
Total Assets	$519.48M	$494.46M	$499.50M	$461.54M
Current Liabilities	$49.04M	$56.23M	$67.66M	$77.80M
Long-Term Debt	$2.27M	$1.65M	$1.05M	$525.00K
Total Debt	$18.09M	$14.14M	$17.02M	$23.74M
Total Liabilities	$93.93M	$101.39M	$103.76M	$119.80M
Retained Earnings	-$17.03M	-$29.18M	-$35.20M	-$101.74M
Shareholders' Equity	$425.30M	$393.06M	$395.74M	$341.74M
Working Capital	$404.98M	$335.83M	$328.78M	$314.19M

CTKB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$12.23M	$5.28M	$25.38M	-$4.69M
Capital Expenditure	-$9.87M	-$4.83M	-$3.73M	-$4.19M
Free Cash Flow	-$22.10M	$454.00K	$21.65M	-$8.88M
Depreciation & Amortisation	$5.66M	$9.23M	$10.49M	$11.97M
Stock-Based Compensation	$16.59M	$22.05M	$26.85M	$24.59M
Investing Cash Flow	-$55.91M	-$93.89M	-$82.97M	$10.12M
Financing Cash Flow	$5.51M	-$41.81M	-$15.82M	-$13.43M
Share Repurchases	$0.00	-$44.15M	-$21.61M	-$15.07M
Net Change in Cash	-$62.63M	-$130.43M	-$73.42M	-$8.00M

CTKB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$41.46M	$45.60M	$52.29M	$62.14M	$44.13M	$48.14M
Cost of Revenue	$21.30M	$21.73M	$24.74M	$29.26M	$22.88M	$19.80M
Gross Profit	$20.16M	$23.87M	$27.55M	$32.88M	$21.25M	$28.34M
Research & Development	$9.72M	$8.83M	$8.96M	$8.96M	$9.60M	$9.74M
Selling, General & Admin	$25.41M	$25.66M	$27.79M	$29.52M	$30.11M	$30.00M
Operating Expenses	$35.13M	$34.49M	$36.74M	$38.48M	$39.72M	$39.74M
Operating Income	-$14.97M	-$10.62M	-$9.19M	-$5.59M	-$18.46M	-$11.40M
EBITDA	-$8.09M	-$3.37M	-$4.21M	-$1.71M	-$14.30M	-$8.38M
Pretax Income	-$11.27M	-$6.78M	-$7.77M	-$4.03M	-$17.37M	-$11.64M
Income Tax	$136.00K	-$1.19M	-$2.29M	$40.05M	$1.49M	$515.00K
Net Income	-$11.40M	-$5.58M	-$5.48M	-$44.08M	-$18.87M	-$12.16M
Diluted EPS	-0.09	-0.04	-0.04	-0.34	-0.15	-0.09
Diluted Shares	128.34M	126.93M	127.55M	128.17M	128.70M	129.46M

CTKB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$95.30M	$75.47M	$93.28M	$90.85M	$65.67M	$73.85M
Receivables	$55.21M	$56.67M	$61.67M	$72.13M	$56.48M	$51.30M
Inventory	$45.35M	$49.49M	$51.65M	$48.43M	$49.79M	$52.25M
Current Assets	$380.50M	$382.82M	$388.49M	$392.00M	$379.30M	$377.93M
Total Assets	$482.60M	$493.32M	$494.92M	$461.54M	$449.11M	$446.93M
Current Liabilities	$67.69M	$73.27M	$75.21M	$77.80M	$80.94M	$84.33M
Long-Term Debt	$918.00K	$791.00K	$655.00K	$525.00K	$386.00K	$246.00K
Total Debt	$15.90M	$23.68M	$24.83M	$23.74M	$27.48M	$26.46M
Total Liabilities	$102.97M	$115.76M	$116.35M	$119.80M	$121.47M	$124.98M
Retained Earnings	-$46.60M	-$52.18M	-$57.66M	-$101.74M	-$120.60M	-$132.76M
Shareholders' Equity	$379.62M	$377.56M	$378.57M	$341.74M	$327.64M	$321.95M
Working Capital	$312.81M	$309.56M	$313.28M	$314.19M	$298.37M	$293.60M

CTKB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$125.00K	$108.00K	-$3.90M	-$771.00K	-$2.74M	$1.37M
Capital Expenditure	-$851.00K	-$1.65M	-$655.00K	-$1.03M	-$2.20M	-$2.24M
Free Cash Flow	-$976.00K	-$1.54M	-$4.55M	-$1.80M	-$4.94M	-$877.00K
Depreciation & Amortisation	$2.88M	$2.99M	$3.06M	$3.04M	$2.81M	$2.98M
Stock-Based Compensation	$6.63M	$6.79M	$5.64M	$5.53M	$4.86M	$5.34M
Investing Cash Flow	$9.45M	-$16.41M	$18.92M	-$1.84M	-$27.08M	$7.02M
Financing Cash Flow	-$11.54M	-$2.60M	$1.94M	-$1.23M	$3.98M	-$814.00K
Share Repurchases	-$10.63M	-$4.51M	$29.00K	$34.00K	$0.00	$0.00
Net Change in Cash	-$2.22M	-$18.91M	$16.96M	-$3.84M	-$25.83M	$7.58M

Market Snapshot

About

Cytek Biosciences, Inc. is a cell analysis solutions company headquartered in Fremont, California, that develops and manufactures advanced flow cytometry platforms for biomedical research and clinical applications. The company's proprietary Full Spectrum Profiling technology enables researchers to analyze more cellular characteristics simultaneously than traditional flow cytometry systems. Cytek's flagship products include the Aurora and Northern Lights systems, which serve academic institutions, pharmaceutical and biotechnology companies, and clinical laboratories worldwide. The company's technology is used in immunology, oncology, stem cell research, and other fields requiring detailed cellular analysis.